Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN1117 plus docetaxel versus docetaxel in advanced non-small cell lung cancer
NL-OMON42595Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Jun 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MLN1117 plus docetaxel with Docetaxel alone (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2015; status: withdrawn.
02
Drugs
serabelisibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON42595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42595.